Mymd Pharmaceuticals (NASDAQ:QCLS – Get Free Report) and Ainos (NASDAQ:AIMD – Get Free Report) are both small-cap technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.
Profitability
This table compares Mymd Pharmaceuticals and Ainos’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mymd Pharmaceuticals | N/A | -88.18% | -42.59% |
| Ainos | -11,912.10% | -217.50% | -67.87% |
Earnings and Valuation
This table compares Mymd Pharmaceuticals and Ainos”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mymd Pharmaceuticals | N/A | N/A | -$11.63 million | ($20.69) | -0.13 |
| Ainos | $120,000.00 | 87.33 | -$14.77 million | ($2.52) | -0.56 |
Mymd Pharmaceuticals has higher earnings, but lower revenue than Ainos. Ainos is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Mymd Pharmaceuticals has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, Ainos has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and price targets for Mymd Pharmaceuticals and Ainos, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mymd Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Ainos | 1 | 0 | 0 | 0 | 1.00 |
Insider and Institutional Ownership
9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Comparatively, 9.8% of Ainos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Mymd Pharmaceuticals beats Ainos on 6 of the 10 factors compared between the two stocks.
About Mymd Pharmaceuticals
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
About Ainos
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
Receive News & Ratings for Mymd Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mymd Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
